CELUW
MaterialsCelularity Inc - Warrants (16/07/2026)
Live · NASDAQ · May 9, Close
What's Moving CELUW Today?
No stock-specific AI insight has been generated for CELUW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
CELUW News
20 articles- NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of DirectorsYahoo Finance·May 6, 2026
- Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic TransformationYahoo Finance·May 1, 2026
- NEXGEL Appoints Ian Blackman as Chief Financial OfficerYahoo Finance·Apr 27, 2026
- NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease SegmentYahoo Finance·Apr 21, 2026
- Celularity Announces Closing of Transaction with NexGelYahoo Finance·Apr 21, 2026
- NEXGEL, Inc. Q4 2025 Earnings Call SummaryMoby·Apr 21, 2026
- Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingYahoo Finance·Apr 17, 2026
- NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity TransactionYahoo Finance·Apr 15, 2026
- NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity TransactionYahoo Finance·Apr 8, 2026
- NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with CelularityYahoo Finance·Mar 31, 2026
- Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye CareYahoo Finance·Oct 30, 2025
- Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery DiseaseYahoo Finance·Oct 14, 2025
- Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) ComplianceYahoo Finance·Sep 3, 2025
- Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024)Yahoo Finance·Aug 31, 2025
- Celularity Receives Nasdaq Notice Regarding Form 10-QYahoo Finance·Aug 22, 2025
- Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured DebtYahoo Finance·Aug 18, 2025
- Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last weekYahoo Finance·Aug 14, 2025
- Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida LawYahoo Finance·Jul 9, 2025
- Celularity Hails New Florida Law Opening Patient Access to Stem Cell TherapiesYahoo Finance·Jul 1, 2025
- Celularity Announces Chief Financial Officer TransitionYahoo Finance·Jun 10, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Celularity Inc - Warrants (16/07/2026)
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.